Description
Summary
Lead strategic sourcing and evaluation of external assets and technologies that enhance the administration and delivery of Immunoglobulin (Ig) products. This role will focus on identifying innovative formulation technologies, delivery devices, and enabling platforms that improve patient experience, optimize dosing, and strengthen our competitive position. The ideal candidate combines deep technical expertise with strong business development acumen and a proven ability to drive partnerships from early engagement through deal close.
MainResponsibilities & Accountabilities
1. Lead proactive sourcing efforts for technologies and assets across all stages of development that improve Immunoglobulin product administration, including advanced formulations, novel delivery devices, and patient-centric solutions.
2. Develop and execute partnering strategies for onboarding innovative technologies, creating competitive advantage and accelerating time-to-market.
3. Engage with external innovators, device manufacturers, and technology providers, building strong relationships and assessing strategic fit.
4. Drive cross-functional due diligence for selected opportunities, coordinating technical, regulatory, clinical, and commercial assessments to inform governance decisions.
5. Collaborate closely with BD leadership to advance high-priority opportunities through negotiation and deal close.
6. Represent the TA externally, leading sourcing activities at specialized conferences and fostering connections with technology networks and academic institutions.
Qualifications & Experience Requirements
7. 12+ years in biopharma or medical device industry with experience in external innovation, technology scouting, or business development.
8. Advanced degree required (PhD in Pharmaceutical Sciences and/or device relevant areas).
9. Deep expertise in formulation science, drug delivery technologies, and device platforms relevant to Immunoglobulin products.
10. Proven track record of structuring and closing technology partnerships.
11. Strong understanding of regulatory pathways and patient-centric design considerations.
#LI-HYBRID
About CSL BehringCSL Behring is a global biotherapeutics leader driven by our promise to save lives. Focused on serving patients’ needs by using the latest technologies, we discover, develop and deliver innovative therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. We use three strategic scientific platforms of plasma fractionation, recombinant protein technology, and cell and gene therapy to support continued innovation and continually refine ways in which products can address unmet medical needs and help patients lead full lives.
CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma. Our parent company, CSL, headquartered in Melbourne, Australia, employs 32,000 people, and delivers its lifesaving therapies to people in more than 100 countries.To learn more about CSL, CSL Behring, CSL Seqirus and CSL Vifor visit and CSL Plasma at .Our Benefits